一、募集资金基本情况 经中国证券监督管理委员会《关于同意申联生物医药（上海）股份有限公司 首次公开发行股票注册的批复》（证监许可[2019]1743 号）核准，并经上海证券 交易所同意，公司发行人民币普通股（A 股）不超过 5,000 万股，发行价格为每 股 8.80 元，募集资金总额 44,000.00 万元，募集资金净额为人民币 40,017.50 万 元。上述资金到位情况已经大华会计师事务所（特殊普通合伙）验证，并由其出 具"大华验字[2019]000402 号"验资报告。 公司对募集资金采取了专户存储制度，设立了相关募集资金专项账户。募集 资金到账后，已全部存放于经公司董事会批准开设的募集资金专项账户内，并与 保荐机构、存放募集资金的银行签署了《募集资金三方监管协议》。 2022 年 4 月 28 日，公司披露了《申联生物医药（上海）股份有限公司关于 首次公开发行股票募投项目结项并将节余募集资金用于实施动物灭活疫苗项目 及永久补充流动资金的公告》，拟将首次公开发行募集资金投资项目"悬浮培养 口蹄疫灭活疫苗项目"结项，并将节余募集资金 9,903 万元用于实施动物灭活疫 苗项目，结余募集资金剩余部分永久 ...

证券代码：688098 证券简称：申联生物 公告编号：2023-032 申联生物医药（上海）股份有限公司 自愿披露关于签署《抗非洲猪瘟的蓝耳病基因工程活载体 疫苗技术开发（合作）合同》的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 事项概述：申联生物医药（上海）股份有限公司（以下简称"公司"） 近日与中国农业科学院上海兽医研究所（以下简称"上兽研"）签署了《抗非 洲猪瘟的蓝耳病基因工程活载体疫苗技术开发（合作）合同》，双方拟共同开 发抗非洲猪瘟的蓝耳病基因工程活载体疫苗，该疫苗能同时预防非洲猪瘟和猪 蓝耳病。 重要风险提示：疫苗产品具有研发周期长、技术难度大、研发风险高等 特点，同时受到外部环境以及行政审批等因素的影响，存在研发失败及不能商 业化生产、销售的风险。请投资者谨慎决策、注意投资风险。 公司近日与上兽研签署了《抗非洲猪瘟的蓝耳病基因工程活载体疫苗技术开 发（合作）合同》，双方拟共同研究开发抗非洲猪瘟的蓝耳病基因工程活载体疫 苗。根据《上海证券交易所科创板股票上市规则》《公司章程》等相关规定，本 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥123.07 million, a decrease of 10.99% compared to the same period last year[17]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥9.93 million, down 57.35% year-on-year[17]. - The net cash flow from operating activities was negative at approximately -¥43.83 million, indicating a decline in operational efficiency[17]. - Basic earnings per share for the first half of 2023 were ¥0.02, a decrease of 66.67% compared to the same period last year[18]. - The company's total assets as of the end of the reporting period were approximately ¥1.55 billion, a decrease of 3.27% from the end of the previous year[17]. - The company's operating revenue decreased by 15.19 million yuan, representing a decline of 6% year-on-year due to reduced government procurement sales of foot-and-mouth disease vaccines[19]. - Gross profit decreased by 15.34 million yuan, with the total profit decline closely matching the gross profit decrease[20]. Research and Development - Research and development expenses accounted for 33.31% of operating revenue, an increase of 15.18 percentage points compared to the same period last year[18]. - The total R&D investment reached ¥40,991,454.92, a significant increase of 63.52% compared to ¥25,068,739.52 in the previous year, with the proportion of R&D investment to operating income rising to 33.31% from 18.13%[63]. - The company is actively developing mRNA vaccines and drugs, with a production facility under construction for this purpose[46]. - The company has established multiple technology platforms, including inactivated vaccines and synthetic peptide vaccines, and is progressively building an mRNA technology platform to enhance its core competitiveness[54]. - The company has achieved significant advancements in its inactivated vaccine technology platform, including five key core technologies that improve vaccine safety and effectiveness[55]. Market Position and Strategy - The company is a high-tech enterprise specializing in the R&D, production, and sales of veterinary biological products, with a focus on vaccines for major animal diseases[24]. - The company is actively pursuing market-oriented sales, which are still in a growth phase but have not yet reached maturity[19]. - The company has established a stable supply chain with suppliers, ensuring timely and quality delivery of raw materials[33]. - The sales strategy includes both government procurement and market-based sales, with a focus on large-scale farming clients and strategic partnerships[35]. - The company is expanding its product offerings to include pet biological products, reflecting a strategy to diversify into new markets[48]. Regulatory and Compliance - The report indicates that the financial statements have not been audited, which may affect investor confidence[6]. - The regulatory environment is becoming stricter, with new drug registration processes expected to take 7-8 years or longer, increasing the investment required for R&D[46]. - The company is adhering to national policies aimed at enhancing the quality and safety of veterinary drugs, which may impact operational strategies[45]. - The company is committed to maintaining compliance with evolving regulations, which is critical for sustaining its market position[46]. Environmental Responsibility - In the first half of 2023, the company invested 1,145,300 CNY in environmental protection[137]. - The total wastewater discharge in the first half of 2023 was 2,600.1 tons, with chemical oxygen demand at 2.3021 tons, well below the limit of 500 mg/l[138]. - The company has established a sound environmental protection mechanism and effectively managed waste emissions[137]. - The company has installed online monitoring facilities for various pollutants, ensuring real-time monitoring of emissions and compliance with environmental standards[148]. Corporate Governance - The company has committed to improving its governance structure to protect the rights of shareholders, especially minority shareholders[167]. - The company will ensure compliance with legal and regulatory requirements in its operations and governance practices[167]. - The company has established a fundraising management system to ensure that raised funds are used legally and appropriately, with a focus on expanding the variety and production scale of foot-and-mouth disease vaccines[166]. - The company has pledged to take legal responsibility for any violations of its commitments regarding competition and related-party transactions[165]. Product Development and Innovation - The company has successfully developed a range of vaccines and diagnostic products, showcasing its capabilities in innovation and product development[47]. - The company has received product approval for several diagnostic kits, including those for African swine fever and foot-and-mouth disease, expanding its diagnostic product pipeline[61]. - The company is focusing on enhancing its independent control capabilities in the synthetic peptide supply chain by promoting domestic resource utilization[58]. - The company has achieved product approval for the bivalent inactivated vaccine for foot-and-mouth disease (FMD) in cattle and sheep, with a total investment of RMB 2.8 billion and RMB 1.21 billion spent in the current period[70]. Financial Management - The company's cash and cash equivalents increased to ¥148,836,724.48, representing 9.59% of total assets, a 182.19% increase compared to the previous year[118]. - The company's trading financial assets decreased to ¥90,445,579.28, accounting for 5.83% of total assets, a decline of 70.36% year-over-year[118]. - The company reported a significant increase in prepayments, which rose by 126.71% to ¥6,204,374.78, representing 0.40% of total assets[118]. - The company has completed the construction of the animal live vaccine workshop, which has a planned area of 6,093.04 square meters and an expected annual production capacity of 70 million doses[123].

证券代码：688098 证券简称：申联生物 公告编号：2023-031 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 申联生物医药（上海）股份有限公司 重要内容提示： 关于参加 2023 年半年度制药及生物制品行业 会议线上交流时间：2023 年 9 月 7 日(星期四)下午 13:00-15:00 集体业绩说明会的公告 本次业绩说明会以网络文字互动形式召开，公司将针对 2023 年半年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议线上交流时间：2023 年 9 月 7 日下午 13:00-15:00 （二）会议召开方式：网络文字互动 （三）网络文字互动平台：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：网络文字互动 线 上 文 字 互 动 平 台 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadsho ...

二、监事会会议审议情况 证券代码：688098 证券简称：申联生物 公告编号：2023-030 申联生物医药（上海）股份有限公司 第三届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 申联生物医药（上海）股份有限公司（以下简称"公司"）第三届监事会第 七次会议于 2023 年 8 月 29 日以现场结合通讯方式召开，本次会议通知已于 2023 年 8 月 19 日以邮件方式送达公司全体监事。本次会议由监事会主席叶尔阳先生 主持，会议应出席监事 3 名，实际出席监事 3 名，会议的召集和召开程序符合 《中华人民共和国公司法》和《公司章程》等相关规定，会议形成的决议合法、 有效。 （一）审议通过《关于审核<2023 年半年度报告>及其摘要的议案》 监事会审核了公司《2023 年半年度报告》及其摘要，了解并监督了半年度报 告的编制及审议程序，全体监事列席董事会并了解董事会对半年度报告的审议情 况。监事会认为《2023 年半年度报告》的编制、审核以及董事会的审议程序符合 法律法规、 ...

证券代码：688098 证券简称：申联生物 公告编号：2023-029 申联生物医药（上海）股份有限公司 2023 年 1-6 月募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 申联生物医药（上海）股份有限公司（以下简称"公司"）董事会根据中国证券 监督管理委员会(以下简称"证监会")《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》及《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》等相关法律、法规及规范性文件的规定，编制 了 2023 年 1-6 月关于公司首次公开发行 A 股股票募集资金存放与实际使用情况的 专项报告。现将截至 2023 年 6 月 30 日公司募集资金存放与实际使用情况专项说明 如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据证监会作出的《关于同意申联生物医药（上海）股份有限公司首次公开发 行股票注册的批复》（证监许可[2019]1743 号），同意公司向社会公开发行人民币普 通股（ ...

公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 申联生物医药（上海）股份有限公司（以下简称"公司"）近日通过了农业 农村部畜牧兽医局兽药临床试验质量管理规范（GCP）的监督检查。公司本次通 过监督检查并符合兽药临床试验质量管理规范（GCP）要求的试验项目信息如下： 公司本次通过兽药临床试验质量管理规范（GCP）监督检查，短期内对公司 申联生物医药（上海）股份有限公司 自愿披露关于通过农业农村部兽药 GCP 监督检查的 公告 | 分类 | 试验项目 | 动物实验场所名称 | | --- | --- | --- | | 兽药临床试 | 猪安全性试验（兽用生物制 | 永登县剑锋养殖场、三门峡市为民实业有 | | | 品） | 限公司、成都茵莱牧业专业合作社 | | 验质量管理 规范（GCP） | 猪有效性试验（兽用生物制 | 永登县剑锋养殖场、三门峡市为民实业有 | | | | 限公司、成都茵莱牧业专业合作社、申联 | | | 品） | 生物医药（上海）股份有限公司兰州分公 | | | | 司（动物实验室） | 证券代码：6880 ...

证券代码：688098 证券简称：申联生物 公告编号：2023-025 申联生物医药（上海）股份有限公司 关于参加 2022 年度生物制品专场集体业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 6 月 14 日(星期三)下午 14:00-15:00 会议召开方式：视频和线上文字互动 视频和线上文字互动平台：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 投资者可于 6 月 13 日(星期二)16:00 前通过邮件、电话将需要了解和关 注的问题提前提供给公司。公司将在文字互动环节对投资者普遍关注的问题进 行回答。 申联生物医药（上海）股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司《2022 年年度报告》，为便于广大投资者更全面深入地了解公司 2022 年年度经营成果、财务状况等信息，公司参与了由上交所主办的 2022 年度 生物制品专场集体业绩说明会，此次活动将采用视频和网络文字互 ...

Financial Performance - The company's operating revenue for 2022 was ¥328.59 million, a decrease of 8.32% compared to ¥358.43 million in 2021[23]. - The net profit attributable to shareholders for 2022 was ¥61.10 million, down 44.56% from ¥110.20 million in 2021[23]. - Basic earnings per share for 2022 were ¥0.15, a decline of 44.44% from ¥0.27 in 2021[24]. - The company's cash flow from operating activities decreased by 89.92% to ¥9.09 million, significantly impacted by delayed sales collections due to economic downturns[26]. - The company achieved an annual revenue of 329 million yuan, a decrease of 8.32% compared to the previous year[41]. - The company reported a total revenue of 18,640.00 million RMB for the year, with a net profit of 3,308.23 million RMB, reflecting a significant increase in performance[88]. - The company’s operating cost was CNY 81,395,617.32, down 6.43% year-on-year, with the main business cost decreasing by 6.47%[128]. - The gross margin for the main business was 75.19%, a decrease of 0.50 percentage points compared to the previous year[130]. - The sales revenue from government procurement was CNY 313,773,594.69, with a slight increase of 2.76% year-on-year[130]. - The market sales revenue dropped to CNY 14,100,343.40, a decrease of 73.11% compared to the previous year[130]. Research and Development - The company has developed unique vaccine technologies, including the i-Molsta and i-Nada, aimed at enhancing vaccine stability and efficacy[13]. - The company's R&D expenses increased by ¥4.09 million, representing 20.56% of operating revenue, up from 19.14% in 2021[24]. - The total R&D investment for the year was ¥67,545,075.67, a decrease of 1.52% compared to the previous year, with a ratio of R&D investment to operating income at 20.56%, up by 1.42 percentage points[85]. - The company has established multiple vaccine technology platforms, including inactivated vaccine, synthetic peptide vaccine, virus-like particle vaccine, and in vitro diagnostic technology platforms, enhancing its core competitiveness[76]. - The company is actively developing new veterinary drugs, including a bivalent inactivated vaccine for foot-and-mouth disease and a trivalent inactivated vaccine for swine diseases, which are currently in the registration phase[94]. - The company is focusing on independent innovation and increasing R&D investment in the veterinary biological products sector[82]. - The company has ongoing projects for vaccines against various diseases, including the African swine fever virus and foot-and-mouth disease[156]. - The company’s R&D investment accounted for 20.56% of operating revenue, which is significantly higher than the industry average of 15.04%[162]. - The company has not canceled any major R&D projects during the reporting period, indicating stability in its development pipeline[158]. Product Development and Innovation - The company launched the "Lian Yuan Jing" vaccine by the end of 2022, marking a significant product introduction[25]. - The company has completed the development of the bivalent inactivated vaccine for foot-and-mouth disease in cattle and sheep and submitted the product approval application[38]. - The company has developed a series of new inactivated vaccines utilizing advanced technologies, including gene engineering and high-efficiency suspension culture technology, addressing industry pain points[72]. - The company is actively advancing the development of mRNA vaccines and has made significant progress in laboratory research[38]. - The company has successfully launched the first-class new veterinary drug, a bivalent inactivated vaccine for foot-and-mouth disease (types O and A), which has received high customer recognition for its effectiveness and safety[72]. - The company has developed and obtained new veterinary drug registration certificates for multiple products, including a bivalent inactivated vaccine for foot-and-mouth disease, which has received approval for production[88]. - The company is expanding its product matrix to include a diverse range of veterinary products, contributing to the development of China's livestock industry[92]. - The company is developing a range of veterinary diagnostic products for major animal diseases, ensuring high sensitivity and specificity in its diagnostic kits[103]. - The company has received product approval for the pig circovirus type 2 subunit vaccine and is in the registration phase for several other vaccines, indicating a diverse product pipeline[78]. Corporate Governance and Compliance - The company is committed to maintaining high standards of corporate governance and transparency in its operations[8]. - The company has received a standard unqualified audit report from Da Hua Accounting Firm, ensuring the accuracy of its financial statements[6]. - The company’s board of directors and management have confirmed the authenticity and completeness of the annual report[5]. - The company emphasizes the importance of risk factors in its management discussion, urging investors to read the relevant sections carefully[5]. - The company has established a quality management system that complies with GMP and ISO9001 standards, enhancing overall quality control[42]. - The company has passed the biosecurity level three protection acceptance and strictly implements GMP management, maintaining controllable biosecurity risks[115]. - The company adheres to strict quality management practices, aligning with national veterinary drug regulations and international quality standards to ensure product quality[104]. Market Position and Strategy - The company is focused on expanding its market presence and enhancing its product offerings in the high-tech biomedical sector[2]. - The company is actively developing a comprehensive technical service and disease prevention solutions to enhance product penetration among end users[60]. - The company aims to optimize its service channels by establishing core service providers and benchmark customers to provide high-quality vaccine products and services to small and medium-sized farms nationwide[60]. - The company is recognized as a high-tech enterprise, benefiting from a reduced corporate income tax rate of 15% for three years, which could be impacted by future re-evaluations[120]. - The company is enhancing its marketing system to increase the market-oriented sales ratio, focusing on the sales of the "Taiji Lian" vaccine and the promotion of the new "Lian Yuan Jing" vaccine[187]. - The company is facing risks related to accounts receivable collection, particularly from government clients, which may be affected by economic downturns[119]. - The company is positioned in a technology-intensive industry with high barriers to entry, requiring significant investment in R&D and compliance with stringent safety and quality standards[69]. Talent and Management - The company implemented a talent strategy focused on optimizing the core management team and enhancing employee career development pathways[45]. - The number of R&D personnel decreased to 67, accounting for 18.36% of the total workforce, down from 23.23% in the previous year[90]. - The company has a core technical team consisting of Nie Dongsheng, Zhang Zhen, Yin Bo, and Ma Guijun, with Yin Bo being a new addition in 2023[200]. - The total pre-tax remuneration for the core technical personnel, including Ma Guijun, was 1 million yuan[200]. - Talent acquisition mechanisms are being improved to attract high-end talent in the biopharmaceutical industry, focusing on training mid-to-senior management personnel[192].

Financial Performance - The company's revenue for Q1 2023 was ¥81,851,831.18, representing a decrease of 8.08% compared to the same period last year[3] - Net profit attributable to shareholders was ¥15,867,632.60, down 33.69% year-on-year[3] - The company reported a net profit margin of approximately 22.0% for Q1 2023, compared to 28.0% in Q1 2022[16] - In Q1 2023, the company reported a net profit of CNY 15,867,632.60, a decrease of 33.5% compared to CNY 23,924,876.69 in Q1 2022[18] - Operating profit for Q1 2023 was CNY 19,162,338.23, down 33.2% from CNY 28,678,434.18 in the same period last year[20] - The company reported a total profit of CNY 19,111,308.51 in Q1 2023, a decrease of 33.1% from CNY 28,629,934.18 in Q1 2022[20] Research and Development - R&D expenses totaled ¥11,254,624.80, which is an increase of 10.54% compared to the previous year, accounting for 13.75% of revenue, up 2.32 percentage points[3] - The company is actively pursuing new technology and product development, with R&D expenses increasing significantly[6] - Research and development expenses increased to CNY 8,757,354.77, up 68.5% from CNY 5,196,621.48 in Q1 2022[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,600,170,365.42, a slight decrease of 0.31% from the end of the previous year[4] - Total assets as of March 31, 2023, were RMB 1,600,170,365.42, slightly down from RMB 1,605,083,700.71 at the end of 2022[13] - Total liabilities decreased to RMB 87,068,037.56 from RMB 108,209,232.05 at the end of 2022, a reduction of 19.5%[14] - Shareholders' equity increased to RMB 1,513,102,327.86 as of March 31, 2023, compared to RMB 1,496,874,468.66 at the end of 2022, an increase of 1.1%[14] Cash Flow - Cash and cash equivalents as of March 31, 2023, were RMB 45,884,713.20, down from RMB 52,742,562.11 at the end of 2022, representing a decrease of 13.4%[12] - Cash flow from operating activities showed a net outflow of CNY 32,986,013.65, an improvement from a net outflow of CNY 42,272,933.50 in Q1 2022[20] - Total cash and cash equivalents at the end of Q1 2023 were CNY 45,727,802.46, down from CNY 53,005,125.45 at the end of Q1 2022[21] - The company generated CNY 33,979,285.31 in cash from sales in Q1 2023, a significant increase from CNY 21,017,968.10 in Q1 2022, representing a growth of 61.2%[20] - Investment activities generated a net cash inflow of CNY 26,338,281.46 in Q1 2023, compared to CNY 51,106,906.26 in Q1 2022[21] Shareholder Information - The top shareholder, Yang Yufang, holds 21.93% of the shares, totaling 90,063,197 shares[8] - The basic earnings per share were ¥0.04, reflecting a decrease of 33.33%[3] - The basic earnings per share for Q1 2023 was CNY 0.04, down from CNY 0.06 in Q1 2022[18] Market and Sales - The company experienced a decline in sales due to delayed government procurement for foot-and-mouth disease vaccines, impacting revenue[6] - The company plans to focus on expanding its market presence and developing new products in the upcoming quarters[10]